Skip to content

Gyre Therapeutics, Inc. GYRE Investment Proceeds

Investment Proceeds at other companies

Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$353.87M+20.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$126.63M-57.2%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$96M+194%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$15.95M+43.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$93.97M+422%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$10M

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s investment proceeds?
Gyre Therapeutics, Inc. (GYRE) reported investment proceeds of $10.07M in Q1 2026.
How has Gyre Therapeutics, Inc.'s investment proceeds changed year-over-year?
Gyre Therapeutics, Inc.'s investment proceeds decreased by 10.0% year-over-year, from $11.19M to $10.07M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.